Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

Pre-Clinical Data Shows Increased Muscle and Blood Vessel Formation in

Animals' Hearts

SUNRISE, Fla., July 24 /PRNewswire-FirstCall/ -- Results of a preclinical study involving the injection of myoblasts modified to express stromal derived factor-1(alpha) protein (SDF-1) into the scar tissue of the myocardium of rats, which suggest improved heart function, were recently presented at two scientific meetings -- the International Society for Magnetic Resonance in Medicine (ISMRM) in Toronto, and the American Society of Gene Therapy Meeting (ASGT) in Boston.

The data, presented by Bijoy Thattaliyath, MD, Post-doctoral Associate, Department of Pediatric Cardiology, University of Florida Health Science Center, showed a decrease of 0.02ml in end systolic volume (0.13ml to 0.11ml) and a 38 percent increase in stroke volume (0.31 ml to 0.43 ml) from three weeks post-myocardial infarction (MI, heart attack) to eight weeks post-cell transplantation, as presented in one of the SDF-1 modified myoblast (SDF-MB) transplanted animals. These results are indicative of 'positive remodeling', or return to normal heart function in the same period. Similar results were found in other study animals. Histopathology confirmed that myoblasts expressing SDF-1 resulted in increased muscle and blood vessel formation in the damaged areas of the hearts, which was not observed in the control.

Additionally, there was an 11.7 percent plus or minus 2.9 percent (p=0.02) absolute improvement in ejection fraction between three weeks post-MI and eight weeks post-cell transplantation in the SDF-MB treated animals. By comparison, and as anticipated, the control arm worsened in the same period. Ejection fraction is the percentage of blood pumped out of the heart's left ventricle with every heartbeat into the body's vasculature. A higher percent ejection fraction means more efficient heart function.

"The study data suggest that SDF-1 modified
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008).../- CEL-SCI Corporation,(NYS... a Material Transfer,Agreement (MTA) with the Nati...and the laboratory of Dr. Francesco M. Marincola, ...s to the tumor microenvironment,caused by CEL-SCI,...f of,the Infectious Disease and Immunogentics Sect...
(Date:10/7/2008)...d Today at ACG Annual Scientific Meeting -, ORLAN...d,Pharmaceuticals, Inc. (formerly Microbia, Inc.) ...announced the presentation of results from a Phase...acy in 420 patients with,irritable bowel syndrome ...dicates that once- daily oral dosing of linaclotid...
(Date:10/7/2008)...ghlighting CIMZIA,s long-term benefits and value i...ented at American College,of Gastroenterology (ACG... Data from two studies,presented this week by UCB ...Annual Meeting demonstrate that CIMZIA(R) (certoli...Tumor Necrosis Factor alpha) - provides,sustained ...
(Date:10/7/2008)...hort Enrolled in Stage A of Trial Assessing Regime...n and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNew.... (Nasdaq: PPHM ), a clinical stage biopharmaceut...the treatment of cancer and,hepatitis C virus (HCV...,enrollment in the first stage of a Phase II trial...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4U S Research Funding Continues to Flatten as U S Health Costs Climb in August 31 Science 258 1U S Research Funding Continues to Flatten as U S Health Costs Climb in August 31 Science 258 2Cepheid to Present at Thomas Weisel Partners Healthcare Conference 282 1Cepheid to Present at Thomas Weisel Partners Healthcare Conference 282 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 1Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 278 1Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 278 2
(Date:10/7/2008)...published ACSM/AHA, guidelines, INDIANAPOLIS and...nes,for physical activity released today by the U....ere met with support from the American College of,...ciation (AHA). The,organizations, which jointly pu...r, attended today,s announcement and said the guid...
(Date:10/7/2008)ANAHEIM, Calif., Oct. 7 /PRNewswire-USNewswire/ -- CHADD, the nation,s,largest organization serving people affected by AD/HD, will hold its Annual,International Conference on AD/HD November 12-1
(Date:10/7/2008)...sive whole-leg color ultrasound, study finds, ...An older, simpler test to look for blood clots in ...is as effective as a newer, more expensive test, n...that 2-point ultrasonography of the leg -- sometim...as good at detecting DVT as the newer, whole-leg, ...
(Date:10/7/2008)... the University of California, San Diego (UCSD) in...arch of advanced lung cancer by treating patients ...ccines attempt to pump up the immune system to fig...tically engineered to also trick the cancer into t...s. , The first patients have begun enrolling in ...
Breaking Medicine News(10 mins):Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
... and college students are now co-authors in a rese...erisation of 30 macrophages has been made possible...ue of June 9, 2006 has a report of a research team...m Hatfull at the University of Pittsburgh. The rep...
...nal of Clinical Nutrition says that the poor healt...r the overweight/obesity epidemic that has the soc...betel nut, it was found that they passed the habit... Boucher, of the University of London, and colleag...
...r that actually quietens the body’s natural pain k...t and non-habit //forming pain killers and will he...Opioid peptides are natural pain relievers with re...y react to opium – throughout the body, says Dr. V...
...tute of Allergy and Infectious Diseases (NIAID), s...r the intended //protection against infection, yet...vaccinated. Such a survival advantage was observe...eams of researchers, one led by Norman L. Letvin, ...
Other Medicine News:Health News:Transporter offers reliable clues for safer pain medicine 2Health News:Transporter offers reliable clues for safer pain medicine 3Health News:HIV Vaccine for Monkeys Increases Survival Rates 2Health News:HIV Vaccine for Monkeys Increases Survival Rates 3
...Intermec has an installed base of field-proven bar...spital departments using Intermec media include; r...y, Admissions, Nursing Stations, Pharmacy, Medical...ing materials includes many products that are fitt...
...MediCopia is a system for inpatient caregiving tha...a's automated computer system offers four technolo...are a handheld computer (for work order processing...cation), thermal printer (for label generation at ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell
The IMAGETEAM 4600 SR / SF area imager from Hand Held Products combines the versatility of area imaging with the speed and cost of linear scanning for healthcare, retail and commercial applications.
Medicine Products: